Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged between and including 18 and 45 years at time of Visit 1~2. Subjects willing to give written informed consent to participate in the trial~3. Subjects who are healthy as determined by medical history, with no clinically significant abnormalities in clinical examination and laboratory tests~Exclusion Criteria:~1. Subjects unwilling to give his/her consent to participate in the trial~2. Subjects who have received Typhoid containing vaccines~3. Subjects who have past history of Typhoid~4. Subjects already immunized with any licensed vaccine within 4 weeks~5. Subjects with known hypersensitivity to any component of the study vaccine~6. Subjects who are pregnant, lactating or childbearing age not using a reliable method of contraception~7. Subjects with any abnormality or chronic disease~8. Subjects with evidence of acute illness within past 7 days requiring systemic antibiotic or antiviral therapy~9. Subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria and/or typhoid~10. Subjects who have known history of immune function disorders~11. Subjects who have known history of administration of blood or blood-derived products~12. Subjects who have history of alcohol or substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Test group (Type: EXPERIMENTAL): Single dose of EuTCV will be administered intramuscularly
- Comparator group 1 (Type: ACTIVE_COMPARATOR): Single dose of Typbar-TCV™ will be administered intramuscularly
- Comparator group 2 (Type: ACTIVE_COMPARATOR): Single dose of Typhim Vi® will be administered intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).